Topline results from a pooled clinical study show that Mainz Biomed’s portfolio of proprietary novel gene expression (mRNA) biomarkers can be used in a next generation version of the company’s colorectal cancer screening tool. The study included new patients and subjects from Mainz Biomed’s ColoFuture (Europe) and eAArly DETECT (U.S.) clinical trials. The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced adenoma of 82%, the company said.
Andrew Smith was named chair of St. Jude’s Diagnostic Imaging Department. He succeeds Beth McCarville, who was interim chair of the department since the death of Zoltan Patay, who held the position from 2017 to 2022.
COTA, a leader in real-world data and analytics for oncology, is entering a collaboration with Sanofi to use RWD and artificial intelligence to increase the speed of oncology trials, including for multiple myeloma.
Regeneron Science Talent Search top three finalists, Thomas Cong, Achyuta Rajaram and Michelle Wei.Achyuta Rajaram, a 17-year-old high school student from Exeter, NH, won $250,000 in a first-place award in the Regeneron Science Talent Search 2024.
Yosemite, an oncology-focused venture capital firm, and the American Cancer Society established the Yosemite-American Cancer Society Award with an initial commitment of $13.2 million.
The Jackson Laboratory (JAX) and LG AI Research signed a partnership agreement creating an alliance between JAX’s expertise in biomedical research and data analysis and LG AI Research’s AI technology and product development experience.
I recently attended a dinner party where guests lamented the use of generative AI in schools. They asked questions like, “Will kids stop learning and plug all their essay prompts into ChatGPT?”
Magentiq-Eye Ltd., an Israel-based technology company founded in 2014, announced today a study on the performance of Magentiq-Colo CADe version has been published in Lancet Digital Health.
As artificial intelligence becomes an indispensable tool in cancer research, drug sponsors and researchers should focus on building and utilizing rich real-world evidence databases that can be used to complement clinical trials.
Fred Hutchinson Cancer Center researchers, led by Jonathan Bricker, launched an AI-powered chatbot app called QuitBot to help more people successfully quit smoking cigarettes.
